Cargando…
Preeclampsia – Will Orphan Drug Status Facilitate Innovative Biological Therapies?
It is generally accepted that the development of novel therapies to treat pregnancy-related disorders, such as preeclampsia, is hampered by the paucity of research funding. Hence, it is with great interest to become aware of at least three novel therapeutic approaches for the treatment of this disor...
Autor principal: | Hahn, Sinuhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341571/ https://www.ncbi.nlm.nih.gov/pubmed/25767802 http://dx.doi.org/10.3389/fsurg.2015.00007 |
Ejemplares similares
-
Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?
por: Hahn, Sinuhe, et al.
Publicado: (2015) -
Neutrophil NETs in reproduction: from infertility to preeclampsia and the possibility of fetal loss
por: Hahn, Sinuhe, et al.
Publicado: (2012) -
Potential markers of preeclampsia – a review
por: Grill, Simon, et al.
Publicado: (2009) -
The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia
por: Yang, Shuangjian, et al.
Publicado: (2022) -
Quantitative Proteomic (iTRAQ) Analysis of 1st Trimester Maternal Plasma Samples in Pregnancies at Risk for Preeclampsia
por: Kolla, Varaprasad, et al.
Publicado: (2012)